{"doi":"10.1016/j.clcc.2020.10.001","title":"Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice","abstract":null,"journal":"Clinical Colorectal Cancer","year":2021,"id":629542,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1630453,"name":"Yong Sang Hong","orcid":null,"position":1,"is_corresponding":false},{"id":1411635,"name":"Ji Sung Lee","orcid":"0000-0001-8194-3462","position":2,"is_corresponding":false},{"id":1483174,"name":"Keun‐Wook Lee","orcid":"0000-0002-8491-703X","position":3,"is_corresponding":false},{"id":1630455,"name":"Hye Sook Han","orcid":null,"position":4,"is_corresponding":false},{"id":131605,"name":"Sun Young Kim","orcid":null,"position":5,"is_corresponding":false},{"id":242060,"name":"Ji-Won Kim","orcid":"0000-0002-2827-0884","position":6,"is_corresponding":false},{"id":1087528,"name":"Hee Kyung Kim","orcid":"0009-0004-6552-9404","position":7,"is_corresponding":false},{"id":1350532,"name":"Jin Won Kim","orcid":"0009-0002-0624-0892","position":8,"is_corresponding":false},{"id":1630459,"name":"Choi Ki Eun","orcid":null,"position":9,"is_corresponding":false},{"id":1361024,"name":"Tae Won Kim","orcid":"0000-0001-9522-1997","position":10,"is_corresponding":false},{"id":284099,"name":"Jeong Eun Kim","orcid":"0000-0002-4368-1243","position":11,"is_corresponding":false},{"id":1630452,"name":"Yeong Hak Bang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice","abstract":"<h4>Background</h4>Anti-vascular endothelial growth factor (VEGF) agents have shown clinical benefits against metastatic colorectal cancer (mCRC) when combined with cytotoxic chemotherapeutic drugs. Because randomized controlled trials have restrictive enrollment criteria, and because the participants typically do not resemble actual patients, we here investigated the efficacy of bevacizumab as part of a combination therapy for mCRC in a Korean real-world practice setting.<h4>Patients and methods</h4>We retrospectively evaluated 3748 patients with an initial diagnosis of mCRC or recurrent colorectal cancer with distant metastasis who received first-line chemotherapy in a tertiary cancer center. The primary study endpoint was overall survival. We used multivariate analysis using the Cox regression hazard model and propensity score matching (PSM) methods to adjust for any confounding clinicopathologic factors. Subgroup analysis was also performed for patients who did not receive local treatments for metastatic lesions before receipt of first-line chemotherapy.<h4>Results</h4>In an initial crude analysis, patients who received first-line FOLFOX or FOLFIRI showed better survival outcomes if these regimens were combined with bevacizumab (median overall survival, 3.5 vs. 2.3 years; hazard ratio [HR] = 0.66; 95% confidence interval [CI], 0.59-0.73; P < .001). However, Cox regression hazard model adjusted analysis using PSM methods revealed no significant survival differences between these groups (3.0 vs. 2.6 years; HR = 0.92; 95% CI, 0.79-1.07; P = .2612). We performed further survival analysis of 2814 patients with unresectable disease without metastasectomy who received metastatic radiofrequency ablation before chemotherapy. Cox regression and PSM analysis indicated that bevacizumab group showed better survival (HR = 0.82; 95% CI, 0.71-0.94; P = .005; and HR = 0.84; 95% CI, 0.71-0.99; P = .018).<h4>Conclusion</h4>The addition of bevacizumab to a first-line chemotherapeutic regimen provides survival benefits in a real-world setting for mCRC patients who cannot undergo curative-intent local treatment for metastatic lesions.","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33223477","pmcid":null,"openalex_id":"https://openalex.org/W3095986263","authors":[],"funders":[{"funder_name":"Korea Foundation","grant_id":"","title":null}],"total_grants":1,"fwci":0.304,"citation_percentile":0.57711509,"influential_citations":0,"citation_trend":[{"year":2022,"count":2},{"year":2023,"count":2},{"year":2024,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1533002820301390?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1533002820301390?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.clcc.2020.10.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33223477","host_type":"repository"}],"fields_of_study":["Colorectal Cancer Treatments and Studies","Colorectal Cancer Surgical Treatments","Hepatocellular Carcinoma Treatment and Prognosis","Adult","Aged","Antineoplastic Agents, Immunological","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Colorectal Neoplasms","Disease-Free Survival","Fluorouracil","Humans","Leucovorin","Male","Middle Aged","Neoplasm Metastasis","Organoplatinum Compounds","Retrospective Studies","Folfox protocol"],"mesh_terms":["Bevacizumab","Antineoplastic Agents, Immunological","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Leucovorin","Fluorouracil","Humans","Male","Middle Aged","Neoplasm Metastasis","Organoplatinum Compounds","Retrospective Studies","Colorectal Neoplasms","Disease-Free Survival"],"keywords":["Bevacizumab","Medicine","Colorectal cancer","Oncology","Internal medicine","Chemotherapy","Irinotecan","Cancer","Survival analysis","Colorectal Neoplasms","Propensity Score","Anti-vegf","Metastasectomy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T18:57:34.417495Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}